It estimated about
"The company estimates that this funding is sufficient to enable us to perform initial human clinical trials of our injectable FluCide drug candidate, as well as possibly to advance our DengueCide orphan drug candidate towards initial human clinical trials," the company said in a release Tuesday.
FluCide is a broad-spectrum anti-influ drug candidate. DengueCide is a drug candidate for treatment of dengue and dengue hemorrhagic fever.
The quarterly earnings were filed Friday. The company stock was trading at
"The company's estimates are based on its current rate of expenditure and also on certain approximate estimates for clinical development of its drug candidate as gleaned from discussions with various contract research organizations,"
The company reported about
The company reported in late January that in March it expects to complete construction of a lab in
(c)2014 The Hartford Courant (Hartford, Conn.)
Visit The Hartford Courant (Hartford, Conn.) at www.courant.com
Distributed by MCT Information Services